ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2023
Spatiotemporal spread of tick-borne encephalitis in the EU/EEA, 2012 to 2020.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Structures of asymmetric particles of tick-borne encephalitis virus provide insight into flavivirus assembly and maturation.Science advances · 2026Article
- Predicting the spatio-temporal risk of human tick-borne encephalitis (TBE) in Europe by combining hazard and exposure drivers.One health (Amsterdam, Netherlands) · 2026Article
- Global risk assessment of Lyme borreliosis transmission.Pathogens and global health · 2026Article
- A Household Cluster of Tick-Borne Encephalitis in Belgium in 2025: Is the Epidemiology Evolving?Viruses · 2026Article
- Development and evaluation of an assay for the detection of tick-borne encephalitis virus RNA via real-time PCR with reverse transcription.Parasites & vectors · 2026Article
- Review
- Genome-wide association study identifiesiScience · 2025Article
- Article
- Review
- Distribution and Genotypic Landscape of Tick-Borne Encephalitis Virus in Ticks from Latvia from 2019 to 2023.Pathogens (Basel, Switzerland) · 2025Article
- Meteorological and environmental factors associated with the exposure to tick-borne encephalitis virus (TBEV) in cattle, north-eastern France, 2018-2019.Veterinary research · 2025Article
- Article
- Seroprevalence of tick-borne infections in blood donors in Europe: a systematic review.New microbes and new infections · 2025Review
- Development of Langat virus infectious clones as a platform for live-attenuated tick-borne encephalitis vaccine.Npj viruses · 2025Article
- Seroprevalence of West Nile, Usutu and tick-borne encephalitis viruses in equids from south-western France in 2023.Veterinary research · 2025Article
- Identifying hotspots and risk factors for tick-borne encephalitis virus emergence at its range margins to guide interventions, Great Britain.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Different environmental factors predict the occurrence of tick-borne encephalitis virus (TBEV) and reveal new potential risk areas across Europe via geospatial models.International journal of health geographics · 2025Article
- Mapping the risk of tick-borne encephalitis in Europe for informed vaccination decisions.Journal of travel medicine · 2025Article
- The Influence of Biogeographic Diversity, Climate and Wildlife on the Incidence of Tick-Borne Encephalitis in Croatia.Viruses · 2025Article
- Neurotropic Tick-Borne Flavivirus in Alpine Chamois (Viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundTick-borne encephalitis (TBE) is a vaccine-preventable disease involving the central nervous system. TBE became a notifiable disease on the EU/EEA level in 2012.AimWe aimed to provide an updated epidemiological assessment of TBE in the EU/EEA, focusing on spatiotemporal changes.MethodsWe performed a descriptive analysis of case characteristics, time and location using data of human TBE cases reported by EU/EEA countries to the European Centre for Disease Prevention and Control with disease onset in 2012-2020. We analysed data at EU/EEA, national, and subnational levels and calculated notification rates using Eurostat population data. Regression models were used for temporal analysis.ResultsFrom 2012 to 2020, 19 countries reported 29,974 TBE cases, of which 24,629 (98.6%) were autochthonous. Czechia, Germany and Lithuania reported 52.9% of all cases. The highest notification rates were recorded in Lithuania, Latvia, and Estonia (16.2, 9.5 and 7.5 cases/100,000 population, respectively). Fifty regions from 10 countries, had a notification rate ≥ 5/100,000. There was an increasing trend in number of cases during the study period with an estimated 0.053 additional TBE cases every week. In 2020, 11.5% more TBE cases were reported than predicted based on data from 2016 to 2019. A geographical spread of cases was observed, particularly in regions situated north-west of known endemic regions.ConclusionA close monitoring of ongoing changes to the TBE epidemiological situation in Europe can support the timely adaption of vaccination recommendations. Further analyses to identify populations and geographical areas where vaccination programmes can be of benefit are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.